Literature DB >> 15807935

Co-infection with HIV and TB: double trouble.

Helen McShane1.   

Abstract

Co-infection with HIV and Mycobacterium tuberculosis is common, particularly in the developing world. Tuberculosis (TB) is the commonest co-infection in HIV-positive individuals, who are at increased risk of both reactivation of latent infection and acquisition of new infection. As the degree of immunosuppression increases, the risks of developing TB disease also increase. The patho-physiology, clinical picture, differential diagnosis and diagnostic tests are discussed, together with the interactions between antiretroviral therapy and anti-tuberculous chemotherapy. Indications for chemoprophylaxis and vaccination against TB are reviewed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15807935     DOI: 10.1258/0956462053057576

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  30 in total

1.  Integration of health services improves multiple healthcare outcomes among HIV-infected people who inject drugs in Ukraine.

Authors:  Chethan Bachireddy; Michael C Soule; Jacob M Izenberg; Sergey Dvoryak; Konstantin Dumchev; Frederick L Altice
Journal:  Drug Alcohol Depend       Date:  2013-09-27       Impact factor: 4.492

2.  Presentation and outcome of tuberculous meningitis among children: experiences from a tertiary children's hospital.

Authors:  Nicolette Nabukeera-Barungi; Jo Wilmshurst; Muloiwa Rudzani; James Nuttall
Journal:  Afr Health Sci       Date:  2014-03       Impact factor: 0.927

3.  Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis.

Authors:  Eszter Lázár-Molnár; Bing Chen; Kari A Sweeney; Emilie J Wang; Weijun Liu; Juan Lin; Steven A Porcelli; Steven C Almo; Stanley G Nathenson; William R Jacobs
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-12       Impact factor: 11.205

4.  Probing the architecture of the Mycobacterium marinum arylamine N-acetyltransferase active site.

Authors:  Areej M Abuhammad; Edward D Lowe; Elizabeth Fullam; Martin Noble; Elspeth F Garman; Edith Sim
Journal:  Protein Cell       Date:  2010-05-08       Impact factor: 14.870

5.  Characterization of the protective T-cell response generated in CD4-deficient mice by a live attenuated Mycobacterium tuberculosis vaccine.

Authors:  Steven C Derrick; Teresa H Evering; Vasan K Sambandamurthy; Kripa V Jalapathy; Tsungda Hsu; Bing Chen; Mei Chen; Robert G Russell; Ana Paula Junqueira-Kipnis; Ian M Orme; Steven A Porcelli; William R Jacobs; Sheldon L Morris
Journal:  Immunology       Date:  2006-10-31       Impact factor: 7.397

6.  HIV/TB co-infection in mainland China: a meta-analysis.

Authors:  Lei Gao; Feng Zhou; Xiangwei Li; Qi Jin
Journal:  PLoS One       Date:  2010-05-20       Impact factor: 3.240

7.  Latent tuberculosis among persons at risk for infection with HIV, Tijuana, Mexico.

Authors:  Richard S Garfein; Rafael Laniado-Laborin; Timothy C Rodwell; Remedios Lozada; Robert Deiss; Jose Luis Burgos; Jazmine Cuevas-Mota; Paris Cerecer; Kathleen Moser; Maria Luisa Volker; Steffanie A Strathdee
Journal:  Emerg Infect Dis       Date:  2010-05       Impact factor: 6.883

8.  High prevalence of latent tuberculosis infection among injection drug users in Tijuana, Mexico.

Authors:  R S Garfein; R Lozada; L Liu; R Laniado-Laborin; T C Rodwell; R Deiss; J Alvelais; A Catanzaro; P G Chiles; S A Strathdee
Journal:  Int J Tuberc Lung Dis       Date:  2009-05       Impact factor: 2.373

Review 9.  Treatment of latent tuberculosis infection in HIV infected persons.

Authors:  Christopher Akolo; Ifedayo Adetifa; Sasha Shepperd; Jimmy Volmink
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

10.  Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services.

Authors:  Laurie Sylla; R Douglas Bruce; Adeeba Kamarulzaman; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2007-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.